The impact of oral Polypodium leucotomos extract on ultraviolet B response: A human clinical study - 14/12/17
Abstract |
Background |
There is a rationale for adding systemic photoprotective agents to the current photoprotection regimen.
Objective |
This study was designed to objectively evaluate the molecular and photobiologic effects of oral administration of Polypodium leucotomos extract (PLE).
Methods |
In all, 22 subjects with Fitzpatrick skin phototype I to III were enrolled. On day 1, subjects were irradiated with visible light, ultraviolet (UV) A1, and UVB (using 308-nm excimer laser). Evaluation was done immediately and 24 hours after irradiation. On days 3 and 4, irradiation and evaluation process was repeated after ingestion of PLE.
Results |
Clinical assessments and colorimetry data showed a decrease in UVB-induced changes in 17 of 22 subjects post-PLE administration; histology findings demonstrated such a decrease in all 22 subjects.
Limitations |
Only 2 doses of PLE were given. Furthermore, subjects with skin phototypes I to III only were studied.
Conclusion |
The results suggest that PLE can potentially be used as an adjunctive agent to lessen the negative photobiologic effects of UVB.
Le texte complet de cet article est disponible en PDF.Key words : colorimetry, cyclobutane pyrimidine dimers, excimer laser, minimal erythema dose, Polypodium leucotomos extract, sunburn cells, ultraviolet
Abbreviations used : COX-2, IGA, MED, PLE, UV
Plan
| Sponsored by Ferndale Healthcare Inc. |
|
| Disclosure: Dr Isedeh is a subinvestigator for Ferndale Laboratories, Estee Lauder, and Clinuvel. Dr Kohli is a subinvestigator for Ferndale Laboratories, Estee Lauder, Johnson and Johnson, and Allergan. Dr Griffith is a subinvestigator for Ferndale Laboratories. Dr Elmets is an investigator and consultant for Ferndale Laboratories. Dr Lim served as a consultant for Pierre Fabre, and received research grant support from Estee Lauder, Ferndale Laboratories, and Allergan. Dr Hamzavi is an investigator for Ferndale Laboratories, Estee Lauder, Allergan, Johnson and Johnson, and Clinuvel. Drs Shafi, Al-Jamal, Silpa-archa, Jackson, Athar, and Kollias have no conflicts of interest to declare. |
Vol 77 - N° 1
P. 33 - juillet 2017 Retour au numéro
Article précédent
- Natural killer cell response is a predictor of good outcome in MCPyV+ Merkel cell carcinoma: A case series of 23 patients
- Valerie Laniosz, Oluwakemi Onajin, Sindhuja Sominidi-Damodaran, Alexander Meves, Lawrence E. Gibson, Christian L. Baum
- Comparison of ultraviolet A light protection standards in the United States and European Union through in vitro measurements of commercially available sunscreens
- Steven Q. Wang, Haoming Xu, Joseph W. Stanfield, Uli Osterwalder, Bernd Herzog
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?